101 related articles for article (PubMed ID: 38596266)
1. Renoprotective strategies.
Raikou VD
World J Nephrol; 2024 Mar; 13(1):89637. PubMed ID: 38596266
[TBL] [Abstract][Full Text] [Related]
2. Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk.
Giorgino F; Vora J; Fenici P; Solini A
Cardiovasc Diabetol; 2020 Nov; 19(1):196. PubMed ID: 33222693
[TBL] [Abstract][Full Text] [Related]
3. Renal dysfunction after off-pump coronary artery bypass surgery- risk factors and preventive strategies.
Maitra G; Ahmed A; Rudra A; Wankhede R; Sengupta S; Das T
Indian J Anaesth; 2009 Aug; 53(4):401-7. PubMed ID: 20640201
[TBL] [Abstract][Full Text] [Related]
4. [REIN Report 2011--summary].
Couchoud C; Lassalle M; Jacquelinet C
Nephrol Ther; 2013 Sep; 9 Suppl 1():S3-6. PubMed ID: 24119584
[TBL] [Abstract][Full Text] [Related]
5. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
Vogt L; Kocks MJ; Laverman GD; Navis G
Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
[TBL] [Abstract][Full Text] [Related]
6. Pemafibrate inhibited renal dysfunction and fibrosis in a mouse model of adenine-induced chronic kidney disease.
Horinouchi Y; Murashima Y; Yamada Y; Yoshioka S; Fukushima K; Kure T; Sasaki N; Imanishi M; Fujino H; Tsuchiya K; Shinomiya K; Ikeda Y
Life Sci; 2023 May; 321():121590. PubMed ID: 36940907
[TBL] [Abstract][Full Text] [Related]
7. Empagliflozin in Patients with Chronic Kidney Disease.
; Herrington WG; Staplin N; Wanner C; Green JB; Hauske SJ; Emberson JR; Preiss D; Judge P; Mayne KJ; Ng SYA; Sammons E; Zhu D; Hill M; Stevens W; Wallendszus K; Brenner S; Cheung AK; Liu ZH; Li J; Hooi LS; Liu W; Kadowaki T; Nangaku M; Levin A; Cherney D; Maggioni AP; Pontremoli R; Deo R; Goto S; Rossello X; Tuttle KR; Steubl D; Petrini M; Massey D; Eilbracht J; Brueckmann M; Landray MJ; Baigent C; Haynes R
N Engl J Med; 2023 Jan; 388(2):117-127. PubMed ID: 36331190
[TBL] [Abstract][Full Text] [Related]
8. In advanced CKD with poorly controlled hypertension, chlorthalidone reduced BP at 12 wk.
Crews DC
Ann Intern Med; 2022 Mar; 175(3):JC29. PubMed ID: 35226524
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.
Agarwal R; Filippatos G; Pitt B; Anker SD; Rossing P; Joseph A; Kolkhof P; Nowack C; Gebel M; Ruilope LM; Bakris GL;
Eur Heart J; 2022 Feb; 43(6):474-484. PubMed ID: 35023547
[TBL] [Abstract][Full Text] [Related]
10. Exosomes isolated from melatonin-stimulated mesenchymal stem cells improve kidney function by regulating inflammation and fibrosis in a chronic kidney disease mouse model.
Yea JH; Yoon YM; Lee JH; Yun CW; Lee SH
J Tissue Eng; 2021; 12():20417314211059624. PubMed ID: 34868540
[TBL] [Abstract][Full Text] [Related]
11. Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease.
Agarwal R; Sinha AD; Cramer AE; Balmes-Fenwick M; Dickinson JH; Ouyang F; Tu W
N Engl J Med; 2021 Dec; 385(27):2507-2519. PubMed ID: 34739197
[TBL] [Abstract][Full Text] [Related]
12. Dyslipidemia in Patients with Kidney Disease.
Thobani A; Jacobson TA
Cardiol Clin; 2021 Aug; 39(3):353-363. PubMed ID: 34247749
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
